Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.63 USD | -5.10% | -4.15% | -24.16% |
Financials (USD)
Sales 2024 * | 40.56M | Sales 2025 * | 41.59M | Capitalization | 1.09B |
---|---|---|---|---|---|
Net income 2024 * | -571M | Net income 2025 * | -585M | EV / Sales 2024 * | 8.04 x |
Net cash position 2024 * | 766M | Net cash position 2025 * | 688M | EV / Sales 2025 * | 9.71 x |
P/E ratio 2024 * |
-1.91
x | P/E ratio 2025 * |
-2.03
x | Employees | 587 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.85% |
Latest transcript on Vir Biotechnology, Inc.
1 day | -5.10% | ||
1 week | -4.15% | ||
Current month | -24.68% | ||
1 month | -23.70% | ||
3 months | -21.34% | ||
6 months | -8.18% | ||
Current year | -24.16% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Sung Lee
DFI | Director of Finance/CFO | 53 | 23-03-26 |
Jennifer Towne
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Sigal
BRD | Director/Board Member | 72 | 20-07-01 |
Robert Perez
BRD | Director/Board Member | 59 | 16-12-31 |
Robert More
BRD | Director/Board Member | 56 | 16-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.90% | 215 M€ | +12.27% | - | |
0.63% | 29 M€ | -4.59% | ||
0.58% | 27 M€ | -5.44% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 7.63 | -5.10% | 901,240 |
24-04-24 | 8.04 | -1.11% | 767,449 |
24-04-23 | 8.13 | +0.37% | 769,272 |
24-04-22 | 8.1 | +1.89% | 1,090,638 |
24-04-19 | 7.95 | -0.13% | 1,079,678 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.16% | 1.09B | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- VIR Stock